Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

0.2249
-0.0335-12.96%
Post-market: 0.22500.0001+0.04%19:59 EDT
Volume:4.73M
Turnover:1.19M
Market Cap:4.52M
PE:-0.12
High:0.2716
Open:0.2550
Low:0.2211
Close:0.2584
52wk High:4.93
52wk Low:0.2211
Shares:20.12M
Float Shares:18.10M
Volume Ratio:1.24
T/O Rate:26.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8267
EPS(LYR):-2.0700
ROE:-8585.26%
ROA:-56.19%
PB:-0.92
PE(LYR):-0.11

Loading ...

Vivos Therapeutics issued new U.S. patent for Vivos CARE devices

TIPRANKS
·
Aug 05

Vivos Therapeutics Wins New US Patent Covering Vivos CARE Oral Device Technology

Reuters
·
Aug 05

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos Care Oral Medical Device Technology

THOMSON REUTERS
·
Aug 05

Top Premarket Decliners

MT Newswires Live
·
Aug 05

Vivos Therapeutics Appoints New Chief Financial Officer

TIPRANKS
·
Aug 04

Vivos Therapeutics - Appoints Roman Franklin as Chief Financial Officer Effective July 31, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 04

Vivos Therapeutics Names Roman Franklin CFO as Bradford Amman Resigns

Reuters
·
Aug 04

Vivos Therapeutics Discloses V-co Investors 4 as Beneficial Owner in Form 3 Filing

Reuters
·
Jul 16

Vivos Therapeutics price target lowered to 75c from $1.75 at Alliance Global

TIPRANKS
·
Jul 09

Vivos Therapeutics Creates New Series A Preferred Stock

TIPRANKS
·
Jul 08

Vivos Therapeutics Files Registration Statement for PIPE Warrant, Conversion Share Resales

Reuters
·
Jul 08

Vivos Therapeutics says Vida oral appliance improves insomnia in study

TIPRANKS
·
Jun 30

Vivos Says Study Shows Vida Oral Appliance Cuts Insomnia Severity in All 37 Patients

Reuters
·
Jun 30

Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline

TIPRANKS
·
Jun 26

Vivos Therapeutics Extends Streeterville Debt-to-equity Conversion Deal Through Aug. 31, 2026

Reuters
·
Jun 26

Vivos Therapeutics Extends Financing Agreement With Streeterville Through August

MT Newswires Live
·
Jun 22

Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity

Reuters
·
Jun 22

Vivos Therapeutics - Streeterville Extends Agreement to Aug 31, 2026, Reaffirms $4.5 Mln Debt Conversion Commitment

THOMSON REUTERS
·
Jun 22

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

THOMSON REUTERS
·
Jun 22

Vivos Therapeutics Plans Rights Offering to Existing Shareholders

TIPRANKS
·
Jun 17